Renalytix AI plc

Renalytix Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded by James McCullough on March 15, 2018 and is headquartered in New York, NY.

Earnings data Q1 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Renalytix Plc engages in the manufacturing of medical devices and equipment. It includes the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The company was founded by James McCullough on March 15, 2018 and is headquartered in New York, NY.

Invitae

SoFi Technologies

Analyst estimates suggest these stocks can deliver eye-popping gains once the rest of the stock market views them in the same light.

3 Growth Stocks Wall Street Thinks Could Rise 50% or More

Targeted testing run rate of 300 diabetic kidney disease patients per week in calendar Q4 2021 Targeted testing run rate of 300 diabetic kidney disease patients per week in calendar Q4 2021

Mount Sinai Initiates System-wide Scale-Up of Renalytix KidneyIntelX™ Enabled Health Care Model

Hims & Hers Health

Inari Medical

All three are rapidly expanding into their own corners of America's $4 trillion per year healthcare sector.

3 High-Growth Healthcare Stocks to Buy in September

NEW YORK and SALT LAKE CITY, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 2021 Wells Fargo Virtual Healthcare Conference.

Renalytix to Present at the 2021 Wells Fargo Virtual Healthcare Conference

Levangie brings extensive commercial operating experience to Renalytix, served on boards of Exact Sciences, Insulet Corporation and Hologic Levangie brings extensive commercial operating experience to Renalytix, served on boards of Exact Sciences, Insulet Corporation and Hologic

Renalytix Appoints Daniel J. Levangie to its Board of Directors

Redfin

There's a stock on this list analysts think can climb by around 47%, as soon as more investors come around to their way of seeing things.

3 High-Growth Stocks That Could Soar by 30% or Better According to Wall Street

Peer reviewed publication in Journal of Medical Economics supports payer coverage for early-stage risk assessment and care management in the primary care office Peer reviewed publication in Journal of Medical Economics supports payer coverage for early-stage risk assessment and care management in the primary care office

Payer Budget Impact Analysis Projects Significant Savings from KidneyIntelX™ Testing at Primary Care Level

Amyris

Nano-X Imaging

These potential stock rockets are well worth the different risks they present.

3 High-Growth Healthcare Stocks to Buy in August

NEW YORK, July 26, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 41st Annual Canaccord Genuity Virtual Global Growth Conference.

Renalytix to Present at the 41st Annual Canaccord Genuity Global Growth Conference

EverBank Financial

Fastly

Find out why these niche businesses keep growing by leaps and bounds.

3 High-Growth Stocks Truly Headed for the Moon

Ocular Therapeutix

Shares of these overlooked gems could make investors very rich once the rest of the market notices their value.

3 Top Life Science Stocks to Buy on Sale Right Now

Renalytix AI plc (RNLX) CEO James McCullough on Q3 2021 Results - Earnings Call Transcript

NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today reported financial results for the quarter and nine months ended March 31, 2021.

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021

Renalytix AI PLC (LON:RENX) has seen its shares fall back after losses surged in the third quarter. The company, a developer of diagnostic solutions for kidney disease, said the net loss for the three months to the end of March came in at US$8mln, compared to just US$0.7mln for the same period in 2020.

Renalytix AI falls after R&D costs help push it into hefty loss

Announces Change of Auditor to Ernst & Young LLP Announces Change of Auditor to Ernst & Young LLP

Renalytix to Report Financial Results for Fiscal Third Quarter 2021 and Provide Corporate Update

Enabling expertise in sales, population health and value-driven care models Enabling expertise in sales, population health and value-driven care models

Leadership Additions Announced to Support Expanding US Government and Healthcare Provider KidneyIntelX Deployment

Clinicians affirm need for accurate early-stage diabetic kidney disease risk assessment to improve patient outcomes and reduce healthcare costs Clinicians affirm need for accurate early-stage diabetic kidney disease risk assessment to improve patient outcomes and reduce healthcare costs

Utility Study Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care

Partnership marks a long-term commitment to reducing impact of kidney disease in large populations via integration of earlier risk assessment paired with comprehensive disease management Partnership marks a long-term commitment to reducing impact of kidney disease in large populations via integration of earlier risk assessment paired with comprehensive disease management

Atrium Health, Wake Forest Baptist Health, Wake Forest School of Medicine and Renalytix Partner to Advance Kidney Health

NEW YORK, May 4, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX) (NASDAQ: RNLX), announced today that COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test, was named as a finalist in the Pandemic Response category of the 2021 World Changing Ideas Awards. "We are honored to be recognized by Fast Company for our Pandemic Response efforts," said Sara Barrington of Kantaro COVID-SeroKlir measures the presence and precise level of IgG antibodies against the receptor-binding domain and the full-length spike protein — the same type of antibodies produced as part of the immune response to COVID-19 virus exposure or generated by a vaccine.

Kantaro's COVID-SeroKlir Antibody Test Named As A Finalist For Fast Company's 2021 World Changing Ideas Awards

Renalytix AI plc (NASDAQ: RNLX) stock is rising on the heels of a 10-year contract from the United States Government to provide KidneyIntelX early-stage kidney disease bioprognostic testing services. The contract, offered through the General Services Administration, covers laboratory testing services that can be provided through more than 140 U.S. government departments, agencies.

Renalytix AI Stock Jumps After 10-Year US Government Contract For Kidney Disease Testing Services

Data from 1,325 CANVAS Participants with Baseline DKD Scored with KidneyIntelX Presented at International Society of Nephrology World Congress of Nephrology 2021 Data from 1,325 CANVAS Participants with Baseline DKD Scored with KidneyIntelX Presented at International Society of Nephrology World Congress of Nephrology 2021

KidneyIntelX Demonstrates Performance and Informs Treatment Decisions in Multinational CANagliflozin CardioVAScular Assessment Study (CANVAS)

Agreement provides RenalytixAI with exclusive option to access intellectual property surrounding a comprehensive panel of novel biomarkers in kidney disease Agreement provides RenalytixAI with exclusive option to access intellectual property surrounding a comprehensive panel of novel biomarkers in kidney disease

RenalytixAI and Joslin Diabetes Center Build on Proprietary Kidney Biomarker Portfolio for KidneyIntelX Platform

Value of KidneyIntelX Testing Demonstrated by Data from 401 Physician Study Presented at National Kidney Foundation 2021 Spring Clinical Meetings Value of KidneyIntelX Testing Demonstrated by Data from 401 Physician Study Presented at National Kidney Foundation 2021 Spring Clinical Meetings

Clinical Utility Study Demonstrates Primary Care Physicians Highly Likely to Order KidneyIntelX to Inform Care Decisions

Clinical findings published in the April issue of Diabetologia, the official journal of the European Association for the Study of Diabetes Clinical findings published in the April issue of Diabetologia, the official journal of the European Association for the Study of Diabetes

Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that under the Company's Employee Share Purchase Plan (“the ESPP”), new 17,652 ordinary shares of £0.0025 each in the capital of the Company (“the Ordinary Shares”) have been issued to settle the purchase of 8,826 American Depositary Shares, each representing two Ordinary Shares (“ADSs”) by employees who participated in the ESPP. Further details in relation to the ESPP were contained in the Company's announcement of 2 September 2020.

News for Renalytix AI plc Stock (RNLX)